These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19196867)

  • 21. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
    Breton CS; Aubry D; Ginet V; Puyal J; Heulot M; Widmann C; Duchosal MA; Nahimana A
    Biochimie; 2015 Sep; 116():141-53. PubMed ID: 26188110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo.
    Formentini L; Moroni F; Chiarugi A
    Biochem Pharmacol; 2009 May; 77(10):1612-20. PubMed ID: 19426698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
    Hasmann M; Schemainda I
    Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
    Cloux AJ; Aubry D; Heulot M; Widmann C; ElMokh O; Piacente F; Cea M; Nencioni A; Bellotti A; Bouzourène K; Pellegrin M; Mazzolai L; Duchosal MA; Nahimana A
    Oncotarget; 2019 Nov; 10(62):6723-6738. PubMed ID: 31803365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
    Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
    Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
    Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
    BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
    Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
    J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
    Biniecka P; Matsumoto S; Belotti A; Joussot J; Bai JF; Majjigapu SR; Thoueille P; Spaggiari D; Desfontaine V; Piacente F; Bruzzone S; Cea M; Decosterd LA; Vogel P; Nencioni A; Duchosal MA; Nahimana A
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
    Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
    Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
    Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
    Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nampt/PBEF/visfatin and cancer.
    Bi TQ; Che XM
    Cancer Biol Ther; 2010 Jul; 10(2):119-25. PubMed ID: 20647743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
    Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
    Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor.
    Kozako T; Aikawa A; Ohsugi T; Uchida YI; Kato N; Sato K; Ishitsuka K; Yoshimitsu M; Honda SI
    Eur J Pharmacol; 2019 Dec; 865():172738. PubMed ID: 31614144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
    Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
    J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
    Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
    Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
    Grohmann T; Penke M; Petzold-Quinque S; Schuster S; Richter S; Kiess W; Garten A
    Leuk Res; 2018 Jun; 69():39-46. PubMed ID: 29653431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
    Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
    Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.